Triazolam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Triazolam

Examples of brand names: Halcion [DE]

ATC code: N05CD05

Main use (for orientation): Sleep disorders

Documented research summary

Separate THC and triazolam treatment arms are not combination studies. Additive impairment remains a plausible, unquantified hypothesis for the pair.

Uncertainties and limitations

Sedation/enzyme plausibility provides risk context, not evidence of a fixed increase in exposure.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Triazolam: CYP3A-mediated breakdown and sedation.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral triazolam; active substance.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0074]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: TRIAZOLAM TABLET [MYLAN PHARMACEUTICALS INC.] [CA_L_D0074]

Source role [CA_P_19949319]: Scope distinction / context

Statement supported: Separate triazolam/THC arms, no combination evidence.

Source: The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users. [CA_P_19949319]

Source role [CA_P_19018520]: Scope distinction / context

Statement supported: Comparator treatments not assessed as pair-specific interactions.

Source: Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. [CA_P_19018520]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0074] TRIAZOLAM TABLET [MYLAN PHARMACEUTICALS INC.]

Original source / bibliographic reference

Authors: Mylan Pharmaceuticals Inc.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_19949319] The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.

Original source / bibliographic reference

Authors: Lile JA, Kelly TH, Hays LR.

Year: 2010

Source type: Controlled Clinical Trial; Comparative Study; Research Support, Non-U.S. Gov't; research-article; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1097/fbp.0b013e32833470d7

PMID: 19949319

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_19018520] Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.

Original source / bibliographic reference

Authors: Lile JA, Kelly TH, Pinsky DJ, Hays LR.

Year: 2009

Source type: Research Support, Non-U.S. Gov't; research-article; Journal Article

DOI: 10.1007/s00213-008-1393-3

PMID: 19018520

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility